deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05198531

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Phase Ib Clinical Study to Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions Recurrent / Metastatic Nasopharyngeal Cancer
Interventions Anlotinib Hydrochloride Capsule Cisplatin Injection Gemcitabine hydrochloride injection TQB2858 Injection
Updated 4 times since 2022 Last updated: Jan 19, 2022 Started: Jan 31, 2022 Primary completion: Oct 31, 2022 Completion: Aug 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05198531, this PHASE1/PHASE2 trial focuses on Recurrent / Metastatic Nasopharyngeal Cancer and remains ongoing. Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Feb 2022 – ~Feb 2024 · 24 months · monthly snapshotRecruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Recruiting → Unknown Status

  4. Feb 2022 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations